ArticleScientific reports2023
Study of 32 new phage tail-like bacteriocins (pyocins) from a clinical collection of Pseudomonas aeruginosa and of their potential use as typing markers and antimicrobial agents.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 30 citations in OpenAlex.
- Prophage-Derived Molecules as Anti-Antibiotics (Basel, Switzerland) · 2026Review
- R pyocin sensitivity ofJournal of medical microbiology · 2026Article
- Identification of an R1-type pyocin previously misannotated as a prophage inMicrobiology (Reading, England) · 2026Article
- Characterization, genomic insights and anti-biofilm potential of phage vB_PaeM_PKMS3, a lytic Pbunavirus capable of infecting clinical Pseudomonas aeruginosa isolates.Antonie van Leeuwenhoek · 2026Article
- Identification and functional insights into new phage tail-like bacteriocins targetingMicrobiology spectrum · 2026Article
- Lipopolysaccharide-targeting treatments for multidrug-resistantExpert opinion on therapeutic targets · 2026Review
- Efagins - engineerable agents that evolved independently to target the enterococcal cell wall.bioRxiv : the preprint server for biology · 2026Article
- Nano-Enabled Delivery of Phage-Based Antibacterials Against ESKAPE Pathogens.Pharmaceutics · 2026Review
- Cyanobacterial flocculation as a defence against bacterial predation.The ISME journal · 2026Article
- Genomic diversification and tailocin-mediated competition in animal-associatedISME communications · 2026Article
- TattleTail: A Rule-Based Tool for Identifying Canonical Pyocin-Encoding Gene Clusters inComputational and structural biotechnology journal · 2026Article
- Role of R5 pyocin in the predominance of high-risk Pseudomonas aeruginosa isolates.Microbiological research · 2025Article
- Current economic and regulatory challenges in developing antibiotics for Gram-negative bacteria.npj antimicrobials and resistance · 2025Review
- Molecular and functional analysis of a putative pyocin S9, with endonuclease activity from P. chlororaphis subsp aurantiaca PB-St2.Archives of microbiology · 2025Article
- Study of the probability of resistance to phage infection in a collection of clinical isolates ofMicrobiology spectrum · 2025Article
- R-pyocins as targeted antimicrobials against Pseudomonas aeruginosa.npj antimicrobials and resistance · 2025Review
- Exploring aggregation genes in aJournal of bacteriology · 2025Article
- Directed evolution of bacteriophages: thwarted by prolific prophage.Applied and environmental microbiology · 2024Article
- Simultaneous clonal spread of NDM-1-producingIJID regions · 2024Article
- Directed evolution of bacteriophages: impacts of prolific prophage.bioRxiv : the preprint server for biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phage tail-like bacteriocins (PTLBs) are large proteomic structures similar to the tail phages. These structures function in bacterial competition by making pores in the membrane of their competitors. The PTLBs identified in Pseudomonas aeruginosa are known as R-type and F-type pyocins, which have a narrow spectrum of action. Their specificity is determined by the tail fiber and is closely related to the lipopolysaccharide type of the target competitor strain. In this study, the genome sequences of 32 clinical of P. aeruginosa clinical isolates were analysed to investigate the presence of R-type and F-type pyocins, and one was detected in all strains tested. The pyocins were classified into 4 groups on the basis of the tail fiber and also the homology, phylogeny and structure of the cluster components. A relationship was established between these groups and the sequence type and serotype of the strain of origin and finally the killing spectrum of the representative pyocins was determined showing a variable range of activity between 0 and 37.5%. The findings showed that these pyocins could potentially be used for typing of P. aeruginosa clinical isolates, on the basis of their genomic sequence and cluster structure, and also as antimicrobial agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.